The aim of this study was to assess clinically meaningful differences of preoperative lower urinary tract symptoms (LUTS) and quality of life (QoL) before and after robot-assisted radical prostatectomy (RARP). Therefore we identified 5506 RARP patients from 2007 to 2018 with completed International Prostate Symptom Score (IPSS) and -QoL questionnaires before and 12 months after RARP in our institution. Marked clinically important difference (MCID) was defined by using the strictest IPSS-difference of − 8 points. Multivariable logistic regression analyses (LRM) aimed to predict ∆IPSS ≤ − 8 and were restricted to RARP patients with preoperatively moderate (IPSS 8–19) vs. severe (IPSS 20–35) LUTS burden (n = 2305). Preoperative LUTS was categorized as moderate and severe in 37% (n = 2014) and 5.3% of the complete cohort (n = 291), respectively. Here, a postoperative ∆IPSS ≤ − 8, was reported in 38% vs. 90%. In LRM, younger age (OR 0.98, 95%CI 0.97–0.99; p = 0.007), lower BMI (OR 0.94, 95%CI 0.92–0.97; p < 0.001), higher preoperative LUTS burden (severe vs. moderate [REF.] OR 15.6, 95%CI 10.4–23.4; p < 0.001), greater prostate specimen weight (per 10 g, OR 1.12, 95%CI 1.07–1.16; p < 0.001) and the event of urinary continence recovery (OR 1.66 95%CI 1.25–2.21; p < 0.001) were independent predictors of a marked LUTS improvement after RARP. Less rigorous IPSS-difference of − 5 points yielded identical predictors. To sum up, in substantial proportions of patients with preoperative moderate or severe LUTS a marked improvement of LUTS and QoL can be expected at 12 months after RARP. LRM revealed greatest benefit in those patients with preoperatively greatest LUTS burden, prostate enlargement, lower BMI, younger age and the event of urinary continence recovery.
Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) occur in men of advanced age and are frequently coexistent. Both may be associated with lower urinary tract symptoms (LUTS) and increased serum PSA levels. To date, it remains unclear whether the association of PCa and BPH reflects a causal link, shared risk factors or pathophysiological mechanisms or detection bias1. Specifically, men suffering from LUTS often seek medical advice and receive PSA testing as part of the clinical evaluation2,3,4,5. In consequence, a substantial proportion of patients diagnosed with PCa and scheduled for radical prostatectomy (RP) suffer from preoperatively clinically important LUTS3,4,5. Such LUTS usually reduce patients’ quality of life (QoL), driven by either storage- (e.g. urgency, nocturia) or voiding-symptoms (e.g. intermittency, weak voiding stream)6,7 and can even have an impact on mortality risk8. Due to such impact on QoL, conventional oncological and functional outcomes, which are integral for PCa patient counselling, should be complemented with the postinterventional prospect of changed symptom burden and quality of life especially in the patients suffering from moderate or severe LUTS, which is often overlooked9.
For outcomes after RARP, this neglect is reflected in the fact that most series focus on postoperative urinary continence recovery10,11, whereas corresponding data on LUTS and QoL is rather sparse12. Moreover, most published series, which focus on latter outcome, are limited by small sample sizes10,11,13,14, particularly of RARP patients with moderate or severe preoperative LUTS2,10. Accordingly, most series rely on exploratory analyses, but forego multivariable analyses (MVA)10,15,16. Similarly, most series focus on changes of mean IPSS or QoL scores but do so without reporting minimal or marked clinically important differences (MCIDs) of pre- vs. postoperative LUTS. Such MCIDs allow easier clinically meaningful interpretation. Finally, aforementioned RARP studies rarely differentiate between storage (e.g. frequency, urgency, nocturia) and voiding-symptoms (e.g. intermittency, weak voiding stream)17. Former might indicate urge incontinence or underlying medical conditions. In consequence, thorough preoperative IPSS evaluation may be essential to better estimate chances of postoperative continence recovery, too2,11.
Thus, we assessed clinically meaningful marked and moderate differences of pre- vs. postoperative LUTS and associated QoL 12 months after RARP and identified predictors of post-RARP improvement.
Material and methods
Within our database, we identified 11,711 PCa patients, who were treated with RARP in our hospital between 5/2006 and 12/2018. Inclusion criteria consisted of complete information on preoperative PSA and pathological characteristics. Functional parameters included urinary function and International Prostate Symptom Score (IPSS) and -QoL questionnaire-derived lower urinary tract symptoms (LUTS) burden preoperatively and at 12 months follow-up. All patients were preoperatively continent. Patients with radiation therapy of the pelvis or prostate (neoadjuvant/salvage/adjuvant), or local therapy of the prostate or bladder, or suspected metastases at preoperative staging were excluded. Finally, we selected 5506 RARP patients for further analysis. Preoperative medication such as: alpha-blocker therapy, 5-alpha-reductase inhibitor therapy, neoadjuvant antiandrogen therapy and/or luteinizing hormone-releasing hormone antagonist or agonist therapy (henceforth referred to as neoadjuvant ADT) did not represent exclusion criteria. No patients received adjuvant or salvage radiation therapy within that timeframe according to our exclusion criteria. The institutional review board at the St. Antonius-Hospital, Gronau, approved the retrospective study design and access to the patients’ medical records. All methods were carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from individual participants in the study.
Urinary continence recovery was defined as a combination of 1) a score ≤ 2 for both the first and second question of the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (Q1 “How often do you leak urine?” and Q2 “How much urine do you usually leak (whether you wear protection or not)?”)18, 2) International Continence Society male questionnaire score ≤ 1 for the questions 2, 3, 4 and finally up to one pad usage within 24 h. Preoperatively, no pad usage was permitted for being deemed continent.
The IPSS score ranges from 0 to 35 points. It consists of the sum of 7 questions, each with a point range from 0 to 5, and one additional QoL question (“If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?”, ranging from 0 (delighted), through 3 (mixed), to 6 (terrible). Symptom burden is categorized as “nothing or mild” (range 0–7 points), “moderate” (range 8–19) or “severe” (range 20–35). The IPSS voiding-subdomain consists of the questions 1, 3, 5 and 6 and ranges from 0 to 20. The IPSS storage-subdomain consists of the questions 2, 4 and 7 and ranges from 0 to 15. Finally, ≤ 2, 3 and > 3 QoL points were categorized as satisfied, mixed and unsatisfied QoL, respectively.
For 12 months after RARP we used the strictest criterion of IPSS-difference of at least 8 points (∆IPSS 8) in relation to the preoperative IPSS score19,20,21, this was defined as a marked clinical important difference (MCID). Specifically, a ∆IPSS ≤ − 8 represents a marked improvement, whereas a ∆IPSS ≥ + 8 would represent a marked deterioration. It is important to note that a marked improvement ∆IPSS ≤ − 8 cannot be observed in those patients with lowest symptom burden (range 0–7 points), since a ∆IPSS ≤ − 8 exceeds any value within that point range. A less rigorous, moderate clinical important difference of ∆IPSS 5 was also utilized15,19,20,21.
Proportions of the MCIDs ∆IPSS 8 and 5 were calculated and stratified according to preoperative LUTS burden mild, moderate, and severe. T-Test was used to compare mean change of IPSS and QoL score per MCID.
Multivariable logistic regression analyses (LRM) aimed to predict a marked improvement, i.e. MCID ∆IPSS ≤ − 8 after 12 months within those with moderate and severe preoperative LUTS.
LRM were adjusted for age, PSA, preoperative LUTS burden (moderate [REF.] vs. severe), prostate specimen weight (g), the Postsurgical Cancer of the Prostate Risk Assessment Score (CAPRA-S)22, nerve-sparing (none vs. uni- vs. bilateral) and bladder neck reconstruction width (1–5 cm). The CAPRA-S is calculated with pre-surgical PSA, pathological Gleason score, surgical margin status, extracapsular extension, seminal vesicle invasion and lymph node invasion22. Similarly, as supplemental analyses, we also performed multivariable linear regression analyses for change of LUTS 12 months after RARP within the total cohort, i.e. those with any preoperative LUTS burden (IPSS range 0–35). Adjustment variables were the same as in LRM.
Within the total cohort, median values of age, BMI, PSA and prostate weight were 65 yrs. (IQR 60–70), 26.5 kg/m2 (IQR 24.6–28.7), 7.3 ng/ml (IQR 5.3–10.6) and 45 g (IQR 36–58), respectively (Table 1). Of all 5506 patients 58% had no or mild LUTS, whereas 37% and 5.3% had a moderate to severe LUTS, respectively. Patients with moderate and severe LUTS had lower rates of bilateral NS compared to the patients with no or mild LUTS, 84 and 78% vs. 86%, respectively (p < 0.001). Median surgical bladder neck reconstruction width was constant in all three groups, 2 cm (IQR 2–3). Based on CAPRA-S, 53, 32 and 15% of the patients were categorized as low-, medium and high-risk.
Follow-up and outcomes
Median follow-up of patients without urinary continence recovery was 24 months (IQR 13–49). At 12 months post-RARP, urinary continence recovery rate was 90%. Preoperative vs. 12 months post-RARP median IPSS and QoL scores decreased from 6 (IQR 3–11) to 1 (IQR 1–2) and from 4 (IQR 2–6) to 1 (IQR 0–2), respectively. Similarly, median IPSS voiding-subdomain decreased from 3 (IQR 1–6) to 1 (IQR 0–3), whereas median IPSS storage-subdomain remained virtually unchanged, from 3 (IQR 2–5) to 3 (IQR 2–4). These mean changes of IPSS scores corresponded to preoperative vs. 12 months post-RARP proportions of ≤ mild, moderate and severe LUTS of 58 vs. 82%, 37 vs. 17% and 5.3 vs. 1.1%, respectively. Similarly, satisfied, mixed and unsatisfied QoL proportions were 77 vs. 84%, 13 vs. 9.3% and 10 vs. 6.8%, respectively.
A marked improvement, ∆IPSS ≤ − 8, translated to a QoL mean change of − 1.66 (vs. + 0.14; p < 0.001). Conversely, a marked deterioration, ∆IPSS ≥ + 8 translated to a QoL mean change of + 2.26 (vs. − 0.27; p < 0.001).
Stratification according to preoperative LUTS revealed great differences applying a MCID ∆IPSS 8 (Fig. 1a): Within patients with mild baseline LUTS (n = 3201), 3.9% showed a marked deterioration and 96% no change. Within patients with moderate baseline LUTS (n = 2014), 1.3% showed a marked deterioration, 60% no change and 38% experienced a marked improvement. Finally, within those with severe baseline LUTS (n = 291), 9.6% had no change and 90% had a marked improvement. Patterns were similar, but less distinct for different MCIDs ∆IPSS 5 (Fig. 1b).
LRM analysis of predictors of marked clinical important difference (MCID)
LRM in those RARP patients with moderate or severe preoperative LUTS revealed younger age (OR 0.98, 95% CI 0.97–0.99; p = 0.007), lower BMI (OR 0.94, 95%CI 0.92–0.97; p < 0.001), higher preoperative LUTS burden (severe vs. moderate [REF.] OR 15.6, 95%CI 10.4–23.4; p < 0.001) and greater prostate specimen weight (per 10 g, OR 1.12, 95%CI 1.07–1.16; p < 0.001) as independent predictors of a marked improvement 12 months after RARP, ∆IPSS ≤ − 8 (i.e. at least 8 points less at 12 months after RARP; Table 2). Moreover, urinary continence recovery within 12 months was also a predictive factor for a marked improvement (OR 1.66 95%CI 1.25–2.21; p < 0.001). LRM results were virtually identical for moderate MCIDs ∆IPSS 5 (Table 2). Multivariable linear regression analyses confirmed same predictors within the total cohort with exception of age (Supplemental Table 1).
Previous series with multivariable analyses on examining postoperative changes of LUTS were sparse, heterogeneous and limited by specific selection of variables or small sample size. Thus, we aimed to provide most comprehensive analyses of marked and moderate clinically important differences between pre- vs. post-RARP LUTS and associated QoL in a large cohort of PCa patients. Our findings aim to provide robust decision factors if local PCa treatment such as RARP should be considered as primary therapy9.
Our study revealed several important findings. First, there was a substantial proportion of 42% of PCa patients with moderate or severe preoperative LUTS (n = 2305). These patient numbers are more than 30-fold compared to previous series2,10. Such sample size represents a prerequisite to identify predictors of LUTS improvement in multivariable analyses. Moreover, such extent of pre-existing LUTS burden and associated negative impact on QoL might greatly confound the perceived outcome after local treatment such as RARP, despite otherwise favourable functional and oncological outcomes. In consequence, it is of utmost importance to consider the treatment of the bothering LUTS as core part of the overall therapy23.
Second, RARP patients with moderate and severe preoperative LUTS showed substantial marked clinical improvement rates of 60 and 90%, respectively. It is of note that within the remaining 40% of former group with moderate LUTS, less than 2% experience a marked deterioration. Thus, we display great safety of RARP in this regard, at least in experienced centers. Conversely, we not only confirm postoperative improvement, but even demonstrate greater potential of LUTS improvement after RARP, even beyond previous reports15, since we applied the most rigorous MCID ∆IPSS ≤ − 8.
Third, there is a statistically significant association between LUTS burden and unfavourable pathological cancer characteristics as evidenced by increasing proportions of CAPRA-S high-risk from 14 to 19% (p < 0.001). These findings support the proposed link between BPH and increased risk of PCa and PCa-related mortality from epidemiological studies1,24. Since inverse stage migration trends demonstrate increasing proportions of senior PCa patients with unfavourable PCa characteristics, who receive local treatment such as RARP, those simultaneously suffering from moderate or severe LUTS will be even more prevalent25,26.
Fourth, we clearly demonstrated that the RARP-mediated effect on postoperative LUTS is driven by voiding symptoms. This is in line with a previously proposed substratification2,27 and series that compared pre- vs. postoperative voiding metrics28. In consequence, during surgical work-up the overall IPPS score as well as the voiding-subdomain should be evaluated. Specifically, a larger score in the voiding-subdomain indicates greater possible RARP-mediated improvement effect on LUTS.
Fifth, the study at hand is one of the few to provide LRM to predict marked post-RARP improvement of LUTS2,10,15,16,27. We confirm preoperative LUTS burden as a strong predictor14,15,16. Moreover, larger prostate size and younger age were predictors as well, which are conceivable due to shared risk factors between BPH, associated LUTS and PCa1,24. Specifically, with regard to age, a longitudinal study impressively demonstrated LUTS progression in men over a period of 11 years29.
We also identified lower BMI as predictor. Several series demonstrated LUTS exacerbation in obese men2, often even unrelated to PCa30,31,32,33. In consequence, for those with residual post-RARP LUTS, obesity remains an important target for intervention, which can be already addressed while counselling the patient.
Finally, not surprisingly, urinary continence recovery is contributive for a marked improvement. It is of note that urinary continence recovery is neither a patient characteristic nor a preoperative condition unlike the aforementioned predictors, but a key functional outcome after RARP. Our findings confirm such association between this outcome and LUTS burden2,27. Interestingly, to our knowledge, we are the first to show these predictors in such multivariable fashion. For example, the Japanese RARP series by Haga et al.14 confirmed our finding of preoperative LUTS burden as a main predictor. However, they identified nerve-sparing as predictor, which we are not able to confirm, potentially due to over 96% of patients who had at least unilateral nerve-sparing in our cohort. Conversely, they neither confirmed BMI, nor age nor prostate weight. As acknowledged by the authors, the sample size (n = 200) was limited. Moreover, they did not utilize MCIDs and their proportion of those with moderate or severe LUTS was not categorized. Finally, we included neoadjuvant ADT in our model, which had been rarely examined in previous series. In this context, Togashi et al. did not report any influence on deterioration of postoperative LUTS, consistent with our findings13.
Our study has limitations. First, our data originate from a highly specialized single tertiary referral center and are not necessarily generalizable. Direct comparison to open radical prostatectomy is not possible since our center performs only RARP. However, the presented findings are highly consistent with previous series. Second, LUTS represent a patient-reported outcome. Our data was not complemented by ultrasound post void residual urine (PVR) or maximum urinary flow rates after 12 months to objectively measure the effect of RARP on micturition28. However, direct post-RARP PVR are institutionally measured by suprapubic catheter, which is only removed if PVR is repeatedly below 100 ml. Finally, for purpose of post-RARP erectile function recovery, several patients medicate with phosphodiesterase-5 inhibitors (PDE-5I), which are known to alleviate LUTS in patients with concomitant BPH-LUTS21. Despite removal of the prostate a remaining effect on smooth muscle relaxation in the bladder and supporting vasculature is possible, thus potentially further improving LUTS post-RARP34. However, in our cohort higher LUTS severity was associated with lower potency rates: i.e. for mild vs. severe LUTS the corresponding preoperative potency rates were 52 vs. 37%. Such distribution strengthens our post-RARP findings, i.e. greatest LUTS improvement rates in exactly those with severe preoperative LUTS.
In one of the largest RARP cohorts with preoperative moderate or severe LUTS burden, we observed substantial proportions of patients with marked improvements of LUTS at 12 months after RARP, which translates to improvement of QoL. LRM revealed greatest benefit in those with preoperatively greatest LUTS burden, prostate enlargement, lower BMI, younger age and the event of urinary continence recovery. In presence of such findings, such postoperative functional and QoL prospects are integral for patient counseling regarding to the prostate cancer treatment.
Androgen deprivation therapy, i.e. antiandrogen and/or luteinizing hormone-releasing hormone antagonist or agonist therapy
Body mass index
Benign prostate hyperplasia
Postsurgical Cancer of the Prostate Risk Assessment Score
International Prostate Symptoms Score
Logistic regression model
Lower urinary tract symptoms
Marked clinically important differences
Multivariable cox regression analyses
Prostate specific antigen
Quality of life
Robot-assisted radical prostatectomy
Ørsted, D. D. & Bojesen, S. E. The link between benign prostatic hyperplasia and prostate cancer. Nat. Rev. Urol. 10, 49–54 (2013).
Kim, J. H. et al. Impact of robot-assisted radical prostatectomy on lower urinary tract symptoms and predictive factors for symptom changes: A longitudinal study. Urology 81, 787–793. https://doi.org/10.1016/j.urology.2012.12.038 (2013).
Sarma, A. V. et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: The Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men’s Health Study. Urology 61, 1086–1091. https://doi.org/10.1016/s0090-4295(03)00154-7 (2003).
Latz, I. et al. Lower urinary tract symptoms in relation to region of birth in 95,393 men living in Australia: The 45 and Up Study. World J. Urol. 31, 673–682. https://doi.org/10.1007/s00345-012-0937-7 (2012).
Walz, J. et al. Lower urinary tract symptoms affect one-third of men in a prostate cancer screening population. J. Endourol. 22, 369–376. https://doi.org/10.1089/end.2007.0135 (2008).
Kupelian, V. et al. Nocturia and quality of life: Results from the Boston area community health survey. Eur. Urol. 61, 78–84. https://doi.org/10.1016/j.eururo.2011.05.065 (2012).
Geraerts, I. et al. Prospective evaluation of urinary incontinence, voiding symptoms and quality of life after open and robot-assisted radical prostatectomy. BJU Int. https://doi.org/10.1111/bju.12258 (2013).
Akerla, J. et al. Impact of lower urinary tract symptoms on mortality: A 21-year follow-up among middle-aged and elderly Finnish men. Prostate Cancer Prostatic Dis. 22, 317–323. https://doi.org/10.1038/s41391-018-0108-z (2019).
Boorjian, S. A. et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur. Urol. 61, 664–675. https://doi.org/10.1016/j.eururo.2011.11.053 (2012).
Dommer, L. et al. Lower urinary tract symptoms (LUTS) before and after robotic-assisted laparoscopic prostatectomy: Does improvement of LUTS mitigate worsened incontinence after robotic prostatectomy?. Transl. Androl. Urol. 8, 320–328. https://doi.org/10.21037/tau.2019.06.24 (2019).
Fujimura, T. et al. Longitudinal change of comprehensive lower urinary tract symptoms and various types of urinary incontinence during robot-assisted radical prostatectomy. Neurourol. Urodyn. 38, 1067–1075. https://doi.org/10.1002/nau.23952 (2019).
Ficarra, V. et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur. Urol. 62, 405–417 (2012).
Togashi, K. et al. The effect of frailty on the quality of life and lower urinary symptoms following robot-assisted radical prostatectomy: A longitudinal analysis (FRARP-QL Study). Urol. Oncol. https://doi.org/10.1016/j.urolonc.2020.08.010 (2020).
Haga, N. et al. The impact of nerve-sparing robot-assisted radical prostatectomy on lower urinary tract function: Prospective assessment of patient-reported outcomes and frequency volume charts. Neurourol. Urodyn. 37, 322–330. https://doi.org/10.1002/nau.23297 (2018).
Ahn, T. et al. Improved lower urinary tract symptoms after robot-assisted radical prostatectomy: Implications for survivorship, treatment selection and patient counselling. BJU Int. 123(Suppl 5), 47–53. https://doi.org/10.1111/bju.14717 (2019).
Lepor, H. & Kaci, L. The impact of open radical retropubic prostatectomy on continence and lower urinary tract symptoms: A prospective assessment using validated self-administered outcome instruments. J. Urol. 171, 1216–1219. https://doi.org/10.1097/01.ju.0000113964.68020.a7 (2004).
Lee, D. S. & Lee, S. J. Urodynamic evaluation of patients with localized prostate cancer before and 4 months after robotic radical prostatectomy. Sci. Rep. 11, 3632. https://doi.org/10.1038/s41598-021-83143-x (2021).
Avery, K. et al. ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol. Urodyn. 23, 322–330. https://doi.org/10.1002/nau.20041 (2004).
Barry, M. J. et al. Benign prostatic hyperplasia specific health status measures in clinical research. J. Urol. https://doi.org/10.1097/00005392-199511000-00051 (1995).
Dornbier, R., Pahouja, G., Branch, J. & McVary, K. T. The New American urological association benign prostatic hyperplasia clinical guidelines: 2019 update. Curr. Urol. Rep. 21, 1–10 (2020).
Nickel, J. C. et al. Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia-integrated data from 1,499 study participants. BJU Int. 115, 815–821. https://doi.org/10.1111/bju.12926 (2015).
Punnen, S. et al. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur. Urol. 65, 1171–1177. https://doi.org/10.1016/j.eururo.2013.03.058 (2014).
Finelli, A. et al. Long-term use of 5-alpha-reductase inhibitors is safe and effective in men on active surveillance for prostate cancer. Prostate Cancer Prostatic Dis. 24, 69–76. https://doi.org/10.1038/s41391-020-0218-2 (2021).
Lorenzo, G., Hughes, T. J., Dominguez-Frojan, P., Reali, A. & Gomez, H. Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth. Proc. Natl. Acad. Sci. 116, 1152–1161 (2019).
Leyh-Bannurah, S. R. et al. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: A contemporary population-based update in light of the 2012 USPSTF recommendations. World J. Urol. https://doi.org/10.1007/s00345-018-2396-2 (2018).
Jiang, C., Fedewa, S. A., Wen, Y., Jemal, A. & Han, X. Shared decision making and prostate-specific antigen based prostate cancer screening following the 2018 update of USPSTF screening guideline. Prostate Cancer Prostatic Dis. 24, 77–80. https://doi.org/10.1038/s41391-020-0227-1 (2021).
Aning, J. J. et al. Detailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy. Urol. Oncol. 36(364), e315–364.e322. https://doi.org/10.1016/j.urolonc.2018.05.017 (2018).
Ou, Y. C. et al. Prophylactic robotic-assisted laparoscopic radical prostatectomy for preoperative suspicion of prostate cancer: Experience with 55 cases. Anticancer Res. 36, 4895–4901. https://doi.org/10.21873/anticanres.11054 (2016).
Malmsten, U. G., Molander, U., Peeker, R., Irwin, D. E. & Milsom, I. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: A longitudinal population-based survey in men aged 45–103 years. Eur. Urol. 58, 149–156. https://doi.org/10.1016/j.eururo.2010.03.014 (2010).
Penson, D. F., Munro, H. M., Signorello, L. B., Blot, W. J. & Fowke, J. H. Obesity, physical activity and lower urinary tract symptoms: Results from the Southern Community Cohort Study. J. Urol. 186, 2316–2322. https://doi.org/10.1016/j.juro.2011.07.067 (2011).
Lee, R. K., Chung, D., Chughtai, B., Te, A. E. & Kaplan, S. A. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int. 110, 540–545 (2012).
Mondul, A. M., Giovannucci, E. & Platz, E. A. A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. J. Urol. 191, 715–721 (2014).
Xue, B. et al. Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. Prostate Cancer Prostatic Dis. 23, 465–474. https://doi.org/10.1038/s41391-020-0208-4 (2020).
Giuliano, F. et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur. Urol. 63, 506–516. https://doi.org/10.1016/j.eururo.2012.09.006 (2013).
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Open Access funding enabled and organized by Projekt DEAL. We acknowledge support from the University of Muenster.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Leyh-Bannurah, SR., Wagner, C., Schuette, A. et al. Improvement of quality of life and symptom burden after robot-assisted radical prostatectomy in patients with moderate to severe LUTS. Sci Rep 11, 16757 (2021). https://doi.org/10.1038/s41598-021-95525-2
This article is cited by
Vesicoprostatic muscle reconstruction: a step further for immediate and early urinary continence
World Journal of Urology (2023)
Can men 75 and older safely receive a minimally invasive radical prostatectomy?
Journal of Robotic Surgery (2023)
Two-year quality of life after robot-assisted radical prostatectomy according to pentafecta criteria and cancer of the prostate risk assessment (CAPRA-S)
Scientific Reports (2022)
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.